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IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell
Responsiveness to CpG DNA and Herpes Simplex
Virus-1
Jurjen Tel1, Ruurd Torensma1, Carl G. Figdor1 and I. Jolanda M. de Vries1,2
Human plasmacytoid dendritic cells (pDCs) are found in skin lesions in a wide variety of diseases. The role of
the microenvironment in these lesions on the function of human pDCs remains elusive. We sought to
determine the effect of Th2 cytokines on the ability of human pDCs to respond to CpG oligodeoxynucleotides
(ODNs) and herpes simplex virus in vitro. In this study, we found that the Th2 cytokines, IL-4 and IL-13, modulate
Toll-like receptor 9 (TLR-9)- and herpes simplex virus-induced pDC phenotype and enhance the ability of these
cells to induce allogeneic T-cell responses. Moreover, Th2 cytokines impaired TLR-9-induced secretion of
inflammatory cytokines and chemokines. Taken together, these results demonstrate that Th2 cytokines are
involved in the modulation of pDC function and responsiveness to bacterial- and viral-derived stimuli.
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INTRODUCTION
Dendritic cells (DCs) constitute a family of antigen-presenting
cells defined by their morphology, phenotype, and their
unique capacity to attract and interact with naive T cells
(Steinman, 1991). Following infection or inflammation, they
undergo a complex maturation process, and migrate to lymph
nodes where they present antigens to T cells. Recent prog-
ress in understanding DC activity to produce cytokines has
revealed that myeloid DCs (mDCs) and plasmacytoid DCs
(pDCs) show different susceptibilities to products derived
from pathogens, depending on their Toll-like receptor (TLR)
expression profiles (Kadowaki et al., 2001; Ito et al., 2002,
2005; Schreibelt et al., 2010). The pDCs represent a highly
specialized naturally occuring DC subset that has a major
role in shaping both innate and adaptive immune responses
via the production of type I IFNs (Cella et al., 1999; Liu,
2005; Gilliet et al., 2008). The pDCs are known to secrete
large amounts of type I IFNs after sensing unmethylated CpG
oligonucleotide motifs derived from bacterial and viral
DNA/RNA through their pattern recognition receptor TLR-9
(Krieg, 2002; Gilliet et al., 2008). The pDC-derived type I
IFNs participate in T-cell priming as Th1-inducing cytokines
(Kadowaki et al., 2000; Ito et al., 2005).
Atopic dermatitis (AD) is a chronic inflammatory skin
disease with a complex pathophysiology (Novak et al., 2010).
Patients suffering from AD have a higher susceptibility for
eczema herpeticum caused by the herpes simplex virus-1
(HSV) (Mackley et al., 2002; Wollenberg et al., 2003a).
In AD, DC subsets are recruited from the blood to the skin
through secreted chemokines and have an essential role in
the initiation and amplification of the allergic immune
response (Novak et al., 2010). AD patients harbor increased
numbers of activated circulating CD4þ T cells, and high
numbers of dermis-infiltrating CD4þ T cells (Werfel, 2009).
In early-stage AD, the T cells predominantly produce IL-4,
IL-5, and IL-13, resulting in a Th2 microenvironment (Grewe
et al., 1995). Human pDCs express FceRI, and expression
levels of this receptor directly correlates with the amount of
IgE levels and the atopic status of a patient (Novak et al.,
2004). Furthermore, FceRI triggering impairs pDCs to secrete
large amounts of type I IFNs in response to TLR-9 stimulation
in vitro (Novak et al., 2004). The Th2 microenvironment in
the skin of AD patients is likely to induce pDC apoptosis and
may contribute to the decreased number of pDCs recruited
from the blood detectable in epidermal lesions in patients
with AD (Wollenberg et al., 2002; Novak et al., 2004). Taken
together, the reduced capacity of pDCs to secrete type I IFNs
in response to TLR-9 stimulation by viral antigens after FceRI
receptor triggering might at least in part explain the increased
susceptibility of allergic patients to viral infections (Bussmann
et al., 2008). Another prominent factor in AD lesions is IL-4
produced by Th2 cells. Previous findings showed that IL-4, in
combination with IL-3, negatively regulates survival of pDCs
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(Rissoan et al., 1999). However, the effect of Th2 cytokines
on pDC function upon encountering bacterial- or viral-derived
CpG motifs remains unclear. In this study, we studied the effect
of IL-4 and IL-13 on HSV- and CpG-induced pDC activation.
RESULTS
Human pDCs express the IL-4 receptor
Recently, Ghirelli et al. (2010) showed that freshly isolated
human pDCs express the IL-4 receptor (IL-4R) on mRNA but
not on protein level. However, in our hands freshly isolated
pDCs do express the IL-4Ra (Figure 1). CpG-C- or HSV-
induced pDC activation had no effect on the IL-4Ra expres-
sion levels on human pDCs (Figure 1). IL-4Ra expression
could no longer be detected on CpG-C- and HSV-activated
pDCs upon coincubation with the cytokine IL-4 (Figure 1).
These data evidently demonstrate that freshly isolated and
activated human pDCs express the IL-4Ra.
IL-4 and IL-13 modulate the phenotype of activated human
pDCs
Previous reports showed that IL-4 has a negative regulating
effect on IL-3-induced pDC survival (Kohrgruber et al., 1999;
Rissoan et al., 1999; Son et al., 2006). Rissoan et al. (1999)
demonstrated that soluble CD40L could rescue IL-4-induced
pDC cell death. Moreover, Uchida et al. (2001) showed that
IL-4 does not affect the survival of IL-3 pDCs from AD
patients compared with IL-3 pDCs from healthy subjects
However, the effect of IL-4 in combination with a TLR
ligand has to date not been described. This prompted us
to investigate the effect of IL-4 on TLR-9-activated pDCs.
Figure 2a clearly illustrates that coincubation of pDCs with
IL-4 and the TLR-9 ligand CpG-C left the viability and survival
of pDCs unaffected, whereas pDCs cultured with IL-4 alone
had diminished survival and viability (Figure 2a). Thus, IL-4,
in combination with a TLR-9 ligand, has no effect on the
viability or survival of human pDCs. Next, we determined
the capacity of the Th2 cytokines, IL-4 and IL-13, to modulate
the phenotype of pDCs. The maturation status of pDCs
was studied by CD83 expression levels. Furthermore, the
expression of CD40, CD80, CD86, and major histocom-
patibility complex (MHC) class I and II was analyzed to
determine the capacity to present antigen along with
costimulation. In accordance with the literature, triggering
of TLR-9 via CpG-B and CpG-C induced phenotypical
maturation of human pDCs by means of increased CD83
and CD86 expression (Supplementary Figure S1 online)
(Kerkmann et al., 2003). The addition of IL-4 and IL-13
during pDC activation consistently enhanced the expression
levels of the costimulatory molecule CD86 and the matura-
tion marker CD83 (Figure 2b and c), whereas IL-4 and IL-13
had no effect on the upregulation of CD80 (data not shown).
In contrast, IL-4 and IL-13 reduced the HSV- and TLR-9-
mediated upregulation of the costimulatory molecule CD40
(Figure 2b and c). We also found that IL-4 and IL-13
differently regulated MHC class I and II expression. On one
hand, IL-4 and IL-13 impaired MHC class I upregulation
and, on the other hand, it slightly enhanced MHC class II
expression (Figure 2b and c). Thus, both IL-4 and IL-13 were
capable of modulating the HSV- as well as the TLR-9-induced
pDC phenotype.
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Figure 1. IL-4 receptor expression on fresh and activated human plasmacytoid dendritic cells (pDCs). To assess IL-4 receptor expression levels, freshly isolated
or overnight activated, with CpG-C or herpes simplex virus-1 (HSV) with or without IL-4, pDCs were incubated with phycoerythrin (PE)-labeled anti-IL-4a
antibodies. Receptor expression levels were analyzed by flow cytometry and compared with the appropriate isotype control. These data show that freshly
isolated and activated pDCs express the IL-4 receptor. Data shown are from one representative experiment out of at least three performed.
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IL-4 and IL-13 enhance the allostimulatory capacity of activated
human pDCs
We next studied the effect of IL-4 and IL-13 on pDCs in a
mixed lymphocyte reaction. Overnight activated pDCs, with
or without IL-4 or IL-13, were harvested and cocultured with
allogeneic peripheral blood leukocytes (PBLs). After 4 days
of coculture, proliferation was measured by 3H-thymidine
incorporation. In accordance with previous findings, we
found that TLR-9-activated pDCs have the capacity to evoke
proliferative allogeneic T-cell responses (Figure 3a). Interest-
ingly, and in line with higher CD86 and MHC class II
expression levels, pDCs activated in the presence of IL-4 or
IL-13 induced stronger allogeneic T-cell responses then pDCs
activated through CpGs or HSV alone (Figure 3a and b).
Cytokine analyses of pDC/PBL cocultures showed that pDCs
activated with CpGs and IL-4 induced a mixed Th cytokine
profile based upon the cytokines IFN-g, tumor necrosis
factor-a (TNF-a), IL-2, IL-10, and IL-4 (Figure 3c), whereas no
changes or production was observed for the other measured
cytokines (data not shown). These data demonstrated that the
presence of IL-4 during pDC activation results in a mixed Th1
and Th2 immune response.
TLR-9-induced cytokine and chemokine secretion is impaired
by IL-4
Upon activation through TLR stimulation, pDCs acquire the
ability to recruit other immune cells to the site of inflamma-
tion by the production of cytokines, chemokines, and type I
IFNs. Recent studies showed that soluble factors can affect
the ability of human pDCs to produce type I IFNs in response
to viral or bacterial stimuli (Fabricius et al., 2006, 2010; Son
et al., 2006). Recently, Megjugorac et al. (2010) showed that
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Figure 2. IL-4 and IL-13 modulate the phenotype of Toll-Like receptor 9 (TLR-9)-activated human plasmacytoid dendritic cells (pDCs). Freshly isolated pDCs
were activated overnight with either herpes simplex virus-1 (HSV) or CpG motifs with or without IL-4 or IL-13. (a) Viability, percentage PI/Annexin V, of pDCs
after incubation with IL-3 (.), IL-4 (K), IL-3 þ IL-4 (m), CpG-C (’), and CpG-Cþ IL-4 (~). IL-4 left the viability of CpG-C-activated pDCs unaffected. (b) CpG-
induced activation for 18 hours resulted in upregulation of surface receptor expression of CD40, CD80, CD86, and major histocompatibility complex (MHC)
class I and II (gray filled histograms) compared with the isotype control (dotted lined histograms). IL-4 modulated the expression of surface molecules (thick
black-lined histograms). Data shown are from one representative experiment using CpG-C out of at least five experiments performed. (c) Graphs show the
receptor expression levels of surface molecules CD40, CD80, CD86, and MHC class I and II of activated pDCs relative to CpG-C-activated pDCs. Data shown
are mean values of at least five (CpGs) or three (HSV) independent experiments±SEM. Significant differences as determined using Student’s t-test. MFI, mean
fluorescence intensity.
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IL-4 had no direct effect on the ability of human pDCs to
secrete IFN-l in response to HSV. Therefore, we tested the
effect of IL-4 on the capacity of pDCs to produce other
cytokines in response to HSV and different CpG subclasses.
We found that IL-4 and IL-13 impaired the ability of human
pDCs to secrete IFN-a in response to CpG-C with B40%
and that IL-4 impaired the response to CpG-A with B60%
(Figure 4a and Supplementary Table S1 online). However,
IL-4 had no effect on HSV-induced IFN-a secretion (Figure 4a).
Interestingly, we found that IL-4 and IL-13 impaired IL-6
production of CpG-A- and CpG C-activated pDCs but not
CpG-B-activated pDCs (Figure 4b and Supplementary Table S1
online). Additionally, IL-4 and IL-13 impaired TNF-a secretion
by CpG-B- and CpG-C-activated pDCs (Figure 4b and Supple-
mentary Table S1 online). Furthermore, we analyzed the
presence of the chemokines interferon-g-induced protein 10
(IP-10), macrophage inflammatory protein-1a (MIP-1a), and
RANTES (regulated upon activation, normal T-cell expressed,
and secreted). We found that the IL-4 impaired the secretion of
IP-10, MIP-1a, and RANTES in response to the different CpG
subclasses (Figure 4c). Taken together, we demonstrate that
IL-4 and IL-13 are negative regulators of TLR-9-mediated
cytokine and chemokine production.
DISCUSSION
This study demonstrates that the Th2 cytokines, IL-4 and
IL-13, modulate the capacity of human pDCs to respond to
CpG motifs and HSV. PDCs activated with either HSV or
different CpG motifs in combination with IL-4 or IL-13
demonstrated to have altered phenotypes and diminished
capacity to secrete large amounts of IFN-a and chemokines.
It is now evident that human pDCs can be found in the
skin of patients suffering from inflammatory skin disorders
such as lupus erythematosus (Farkas et al., 2001; Meller et al.,
2005) and psoriasis (Gilliet et al., 2004; Nestle et al., 2005),
or from viral infections (Vanbervliet et al., 2003; Gerlini
et al., 2006), whereas they are absent under normal
conditions (Conrad et al., 2009). The frequencies of ‘‘blood’’
DC subsets in skin lesions of AD patients compared with
healthy controls remain controversial, as there are contra-
dictory reports that demonstrate either the absence or the
presence of blood DCs in the skin lesions of AD patients
(Uchida et al., 2001; Reider et al., 2002; Upham et al., 2002;
Lebre et al., 2008). This controversy is probably because of
the different techniques used to study the number of DCs, but
is also likely to be a result of surface markers that are used to
determine DC subsets.
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Figure 3. IL-4- and CpG-activated plasmacytoid dendritic cells (pDCs) induce increased numbers of IL-4-secreting T cells. (a) Overnight activated pDCs, with
either herpes simplex virus-1 (HSV), CpG-A, CpG-B, or CpG-C with or without IL-4, were harvested and subsequently cocultured with allogeneic peripheral
blood leukocytes (PBLs) in a 1:20 ratio (pDC/PBL). After 4 days of culture and without addition of cytokines, proliferation was measured by 3H-thymidine
incorporation assay. Data shown are from one representative experiment out of at least three performed. (b) Data shown are mean values of measurements
performed at least in triplicate±SEM of three (CpG-A and CpG-B) or five (CpG-C) independent experiments. Proliferation is depicted as relative T-cell
proliferation compared with T cells stimulated with CpG-C-activated pDCs. Significant differences as determined using Student’s t-test. (c) Supernatants of T-cell
cultures were collected at day 2 and cytokine production was analyzed by cytokine bead array. Data shown are the results of three (CpG-A and CpG-B) or five
(CpG-C) independent experiments performed with different donors. c.p.m., counts per minute.
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Three different mDCs subsets, CD16þ , CD1cþ , and
BDCA3þ , have been defined that have the capacity to
produce IL-12 in response to microbial stimuli through TLRs
and, thereby, induce Th1 development (Trinchieri, 1994;
Jarrossay et al., 2001; Kadowaki et al., 2001). Another blood
DC subset, pDCs, are the key effectors in innate immunity
because of their capacity to produce large amounts of type I
IFNs in response to bacterial or viral infections (Cella et al.,
1999; Liu, 2005). Beside IL-12, pDC-derived type I IFNs also
participate in T-cell priming as Th1-inducing cytokines
(Kadowaki et al., 2000; Ito et al., 2005). In the absence of
the appropriate stimulation, pDCs are known to support a Th2
response (Kadowaki et al., 2000). Recently, Lebre et al.
(2008) showed that CD1cþ mDCs, present in peripheral
blood of AD patients, have a decreased capacity to produce
IL-12. Moreover, CD1cþ mDCs from AD patients activated
by polyinosinic–polycytidylic acid in combination with IFN-g
induced increased frequencies of IL-4-producing Th cells and
reduced numbers of IFN-g-producing Th cells compared with
activated mDCs from healthy controls (Lebre et al., 2008). In
this study we described that pDCs from healthy volunteers
activated through TLR-9 and IL-4 induced increasing
frequencies of IL-4-producing T cells compared with T cells
stimulated with TLR-9-activated pDCs. This observation
might be in part explained by the decreased IFN-a secretion
by pDCs in response to CpG motifs in combination with IL-4.
Decreased IFN-a secretion by pDCs contributes to the
maintenance of a Th2 environment and thereby contributes
to the Th2-inducing feedback loop (Figure 5). Additionally,
reduced IFN-a secretion will likely result in decreased
chemokine secretion by fibroblasts and thereby likely affects
the recruitment of pDCs to the lesion (Figure 5). Moreover,
the reduced chemokine and inflammatory cytokine secretion
by the pDCs present in the lesion will also affect the
recruitment of other immune cells. Furthermore, it has been
suggested that the reduction of IFN-a secretion by pDCs in
AD skin lesions leads to a higher susceptibility to viral
infections (Wollenberg et al., 2003b; Bussmann et al., 2008).
Patients suffering from AD have a higher susceptibility for
eczema herpeticum caused by HSV (Mackley et al., 2002;
Wollenberg et al., 2003a). Peng et al. (2007) demonstrated
that AD patients who had eczema herpeticum were less
prone to produce type I IFNs (a/b) and IP-10 compared with
control individuals. Moreover, they showed that all AD
patient groups tested had elevated serum levels of Th2
cytokines (Peng et al., 2007). Previously, Hochrein et al.
(2004) showed that HSV-1 activated pDCs via TLR-9-
dependent and -independent pathways. In this study we
demonstrated that IL-4 did not affect HSV-induced IFN-a
secretion, whereas TLR-9-induced IFN-a secretion was
clearly affected. These data hint to the possibility that trigger-
ing the IL-4 receptor modulates TLR-9-induced signaling.
Notwithstanding that the contribution of each pathway to the
production of IFN-a was unknown, we tested the influence of
IL-4 on HSV-induced IFN-a production in vitro. It appeared
that the TLR-9-dependent and -independent pathways are
redundant when tested using optimal in vitro conditions.
Future research must take into account the local HSV virion
and cytokine concentration to unravel the contribution
of both pathways under in vivo conditions. Based on the
data presented in this study, we predict that—in vivo—
HSV-induced IFN-a production will be inhibited.
Taken together, we demonstrate that IL-4 enhances the
T-cell stimulatory capacity, but negatively regulates TLR-9-
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Figure 4. Toll-Like receptor 9 (TLR-9)-induced cytokine and chemokine secretion is impaired by IL-4. Supernatants of plasmacytoid dendritic cell (pDC)
cultures following incubation with herpes simplex virus-1 (HSV), CpG-A, CpG-B, or CpG-C with or without IL-4 were analyzed for the presence of (a) IFN-a,
(b, left) IL-6, (b, right) tumor necrosis factor-a (TNF-a), (c, left) RANTES (regulated upon activation, normal T-cell expressed, and secreted), (c, middle)
macrophage inflammatory protein-1a (MIP-1a), and (c, right) IP-10. Data shown are mean values of at least three independent experiments±SEM. Significant
difference in cytokine secretion by pDCs as determined by analysis of variance (ANOVA) and Dunnett’s post hoc test compared with CpG-C-activated pDCs.
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mediated cytokine and chemokine secretion by human
pDCs. These new findings might be of particular importance
in patients suffering from atopic diseases, where the presence
of IL-4 or IL-13 in skin lesions might modulate the capacity
of pDCs to respond to bacterial- and/or viral-derived
CpG motifs.
MATERIALS AND METHODS
Cells
Buffy coats were obtained from volunteers after informed consent
and according to the institutional guidelines and adherence to the
Declaration of Helsinki Principles, and pDCs were purified by
positive isolation using anti-BDCA-4-conjugated magnetic microbe-
ads (Miltenyi Biotec, Bergisch-Gladbach, Germany) and adjusted
to 106 cells per ml in X-VIVO-15 (Lonza, Verviers, Belgium)
supplemented with 2% of human serum. PDC purity was routinely
up to 95%, as assessed by double staining BDCA-2/CD123 (Miltenyi
Biotec). PDCs were cultured as indicated with 10 ngml–1 rhIL-3
(Cellgenix, Freiburg, Germany) or activated in the presence
of 5mgml–1 oligodeoxynucleotide (ODN)-CpG-A (ODN 2216;
Axxora), ODN-CpG-B (ODN 2006; Axxora), ODN-CpG-C (M362;
Axxora, San Diego, CA), or with HSV (multiplicity of infection; 100
virus particles per pDC) with or without rhIL-4 (30Uml–1, Cellgenix)
or rhIL-13 (1 mgml–1, R&D Systems, Minneapolis, MN).
Phenotype
The phenotype of pDCs was determined by flow cytometry after
18 hours of activation. The following primary mAbs and the
appropriate isotype controls were used: mIgG1-FITC, mIgG1-
phycoerythrin (PE), mIgG1-antigen-presenting cell (APC), anti-HLA-
ABC-PE (W6/32), anti-HLA-DR/DP-FITC (Q5/13), anti-CD83-PE,
anti-CD83-FITC, anti-CD80-PE, anti-CD86-PE, anti-CD86-APC,
anti-CD124-PE (all from BD Bioscience Pharmingen, San Diego,
CA), and anti-CD40-PE (Beckman Coulter, Mijdrecht, The Nether-
lands). Mean fluorescence intensity and percentage of positive cells
are based upon inclusion of cells in a live cell gate and determined
on a FACSCalibur (BD Biosciences, San Jose, CA).
Cytokine detection
PDCs were cultured overnight at a concentration of 1 105 pDCs
per 100 ml per well in a 96-well round-bottom plate. Supernatants
were collected from pDC cultures after 16 hours of activation, and
IFN-a and IL-6 production was analyzed by murine monoclonal
capture and horseradish peroxidase-conjugated anti-IFN-a antibo-
dies (Bender MedSystems, Vienna, Austria) or anti-IL-6 Abs (Sanquin,
Amsterdam, The Netherlands) using standard ELISA procedures.
TNF-a, RANTES, IP-10, and MIP-1a production was measured using
a human Multiplex kit (Bender MedSystems) according to the
manufacturer’s instructions. To analyze the T-helper cell profile,
supernatants were collected after 2 days of pDC–PBL coculture.
Cytokine production (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12
(p70), TNF-a, TNF-b, and IFN-g) in the supernatant was analyzed
with a human Th1/Th2 Multiplex kit (BenderMed System) according
to the manufacturer’s instructions.
Mixed lymphocyte reaction
The allostimulatory capacity of differently activated pDCs was tested
in a mixed lymphocyte reaction. Allogeneic PBLs were cocultured
with differently activated pDCs in a 96-well round-bottom plate
(pDC/PBL ratio 1:20 with 1 105 PBLs). After 4 days of culture, 1 mCi
per well of tritiated thymidine (GE Healthcare, Eindhoven, The
Netherlands) was added for 16 hours and incorporation was
measured in a beta-counter.
Statistics
All results are shown as mean±SEM. Statistical differences were
determined by Student’s t-tests or by ANOVA and Dunnett’s
post hoc test.
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Figure 5. Model of the impact of the Th2 milieu on plasmacytoid dendritic cell (pDC) function in skin lesions. The Th2 cytokines, IL-4 and IL-13, which
can be found in skin lesions of atopic diseases, have the capacity to modulate the function of human pDCs in response to bacterial- or viral-derived
CpG motifs. This modulation could result in less recruitment of pDCs and other immune cells to the lesion and thereby have an effect on the outcome
of the immune response.
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